4,4,5,5-Tetramethyl-2-(2-methyl-3-(trifluoromethyl)phenyl)-1,3,2-dioxaborolane, 98%, 100mg

Plan phase PLPHi S40x/0.65 objectif IOS corrigé à l'infini. Distance de travail 0,66 mm

4-Iodo-2-methoxy-5-(trifluoromethyl)pyridine, 95%, 100mg

1-Fluoro-4,5-dimethoxy-2-iodobenzene, 95%, 500mg

8,8-Dimethyl-7-oxo-2-azaspiro[3.5]non-5-ene-6-carbonitrile hydrochloride, 98%, 100mg

Quinoline-8-carbaldehyde, 98.0%, 100g

(2-Methylbenzo[d]thiazol-5-yl)boronic acid, 95.0%, 1g

Dacomitinib>98.0%(HPLC)250mg

4-(2,6-Dichloropyrimidin-4-yl)morpholine, 95.0%, 10g

(5-Chloro-2-propoxyphenyl)boronic acid, 95.0%, 25g

5-Methyl-2-(2-trifluoromethyl-phenylamino)-thiazole-4-carboxylic acid ethyl ester, 95.0%, 1g

Biphenyl-2-sulfonyl chloride, 95.0%, 10g

tert-Butyl Sulfide>98.0%(GC)500mL